On Thursday, Canaccord Genuity adjusted its financial outlook for Evolent Health (NYSE:EVH), reducing the price target to $16.00 from the previous $23.00 while reaffirming a Buy rating on the company's shares. The stock, currently trading near its 52-week low of $9.74, appears undervalued according to InvestingPro analysis. The adjustment comes as Evolent Health prepares for what is anticipated to be a rebuilding year in 2025, with expectations of resetting its adjusted EBITDA from a lower starting point.
Analysts at Canaccord Genuity acknowledge the challenges faced by Evolent in the past year, noting the positive aspect of the adjusted Price to Sales (PS) contracting. Despite a significant 67.79% decline in share price over the past year, the company has maintained strong revenue growth of 37.65%. This strategic move is seen as reducing the likelihood of significant negative financial surprises, potentially leading to more stable results, even in unpredictable market conditions like those experienced in 2024.
Evolent Health has reiterated its commitment to achieving long-term revenue growth targets of over 15% and an approximate 20% growth in adjusted EBITDA, based on the 2025 figures and excluding one-time shifts from PS to Technology & Services (T&S). Despite this positive outlook, the fourth quarter results of 2024 remain uncertain and are expected to significantly influence the baseline for 2025's financial guidance. Current market estimates may require considerable adjustments downwards.
The company's stock has experienced a downturn following the business update, with potential for further declines if the upcoming fourth-quarter results, scheduled for February 19, 2025, and 2025 guidance fall short of investor expectations. However, Canaccord Genuity suggests that much of the downside risk may already be reflected in the current stock price. Get deeper insights into Evolent Health's valuation and 12+ additional exclusive ProTips with InvestingPro, including comprehensive analysis of the company's financial health and growth prospects.
Canaccord Genuity remains optimistic about the demand for Evolent's services, emphasizing the company's role in fulfilling a distinct market need. The firm anticipates that Evolent's offerings will continue to attract strong demand. With the adjusted contracting strategy in place, the analysts expect Evolent's financial performance to stabilize and become less risky after the fourth quarter of 2024. Nevertheless, they acknowledge it may take several quarters for the company to fully regain investor confidence. The reiterated Buy rating comes with a revised price target of $16, marking a significant change from the previous target of $23.
In other recent news, major developments have been noted with Evolent Health. Truist Securities has revised its financial outlook for the company, lowering the price target to $15 while maintaining a Buy rating. This is in response to higher-than-expected utilization levels and uncertainty around December trends. Truist has also adjusted its Q4 EBITDA estimates for the company from $30 million to $24 million.
Meanwhile, Stephens analysts have also revised the price target for Evolent Health, reducing it to $12.00 from $16.00, while maintaining an Equal Weight rating. This follows an evaluation of the company's fourth quarter performance and future earnings potential.
RBC Capital Markets has adjusted its outlook on Evolent Health, reducing the price target to $17 from $20, while sustaining an Outperform rating. This revision came after the company reported success in achieving over $100 million of incremental EBITDA year-over-year through successful re-contracting initiatives.
KeyBanc analysts inferred that Evolent Health's implied 2025 EBITDA could exceed $200 million, a figure notably higher than previously anticipated by investors. Lastly, Needham initiated coverage on Evolent Health with a Buy rating, suggesting the stock is undervalued. These are among the recent developments that have shaped the company's financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.